Accelerating Discovery of Novel and Bioactive Ligands With Pharmacophore-Informed Generative Models

TL;DR

This paper introduces TransPharmer, a pharmacophore-informed generative model that effectively produces structurally novel, bioactive ligands, demonstrated by successful case studies including potent PLK1 inhibitors with new scaffolds.

Contribution

The paper presents TransPharmer, a novel model integrating pharmacophore fingerprints with GPT, enabling scaffold hopping and generation of bioactive, structurally novel compounds.

Findings

TransPharmer outperforms existing models in pharmacophore-guided molecule generation.

Three of four designed compounds for PLK1 showed submicromolar activity.

The most potent compound, IIP0943, has a potency of 5.1 nM and high selectivity.

Abstract

Deep generative models have gained significant advancements to accelerate drug discovery by generating bioactive chemicals against desired targets. Nevertheless, most generated compounds that have been validated for potent bioactivity often exhibit structural novelty levels that fall short of satisfaction, thereby providing limited inspiration to human medicinal chemists. The challenge faced by generative models lies in their ability to produce compounds that are both bioactive and novel, rather than merely making minor modifications to known actives present in the training set. Recognizing the utility of pharmacophores in facilitating scaffold hopping, we developed TransPharmer, an innovative generative model that integrates ligand-based interpretable pharmacophore fingerprints with generative pre-training transformer (GPT) for de novo molecule generation. TransPharmer demonstrates superior performance across tasks involving unconditioned distribution learning, de novo generation and scaffold elaboration under pharmacophoric constraints. Its distinct exploration mode within the local chemical space renders it particularly useful for scaffold hopping, producing compounds that are structurally novel while pharmaceutically related. The efficacy of TransPharmer is validated through two case studies involving the dopamine receptor D2 (DRD2) and polo-like kinase 1 (PLK1). Notably in the case of PLK1, three out of four synthesized designed compounds exhibit submicromolar activities, with the most potent one, IIP0943, demonstrating a potency of 5.1 nM. Featuring a new scaffold of 4-(benzo[b]thiophen-7-yloxy)pyrimidine, IIP0943 also exhibits high selectivity for PLK1. It was demonstrated that TransPharmer is a powerful tool for discovery of novel and bioactive ligands.